Morningstar - Comcast Corporation Class A (CMCSA) The DOJ Files an Appeal to Reverse ATTâ€™s Acquisition of Time Warner; ATTâ€™s Shares Undervalued

Report

Morningstar

Neil Macker

EUR 100.00 For Business Accounts Only

The DOJ Files an Appeal to Reverse AT&Tâ€™s Acquisition of Time Warner; AT&Tâ€™s Shares Undervalued

In a surprise move, the Department of Justice has filed an appeal against Judge Leonâ€™s ruling to allow AT&T to acquire Time Warner (now known as WarnerMedia). When the merger was approved, AT&T agreed to keep WarnerMedia separate while the DOJ decided to appeal in order to avoid the DOJ filing for a stay that would have prevented the merger. The DOJ had 60 days to appeal, but when it didnâ€™t within the first week, we assumed it wouldnâ€™t. Judge Leonâ€™s ruling was very thorough, and we think...

13/07/2018 19 EN

Underlying

Comcast Corporation Class A

Comcast is a media and technology company. The company's segments are: Cable Communications, which provides internet, video, voice, and security and automation services in the United States individually and as bundled services at a discounted rate over its cable distribution system to residential and business customers; NBCUniversal, which includes a portfolio of national cable networks that provide a variety of entertainment, news and information, and sports content, regional sports and news networks, international cable networks, and cable television studio production operations; and Sky, which owns a portfolio of pay television channels that provide entertainment, news, sports and movies.

See profile

US20030N1019 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Neil Macker

Other Reports on these Companies

New Street Research

What Policies Matter to Telco’s Success: Supply Side or Demand Side? Or Something Else?

T CEO John Stankey recently said that “I’ve never seen federal policy this supportive of market-based investment in advanced networks.” That statement raises multiple interesting investor related questions about what does, and does not, support investment in advanced networks, including the relative importance of those policies that drive supply and those that drive demand, and how government is treating advanced networks versus networks that have lower cost structures but also involve lower performance metrics. In this note we provide some history and raise those questions so that investors...

EUR 8483.00

February 10, 2026 February 10, 2026 1 EN

New Street Research

CMCSA: The value unlock trade? Nope. No major change in fundamentals

We shared our view of Comcast’s results this morning. Results were in line and commentary on the business fundamentals were mostly unchanged. In this note following the earnings call and our follow-up conversations, we address the following key investor issues including 1) the big picture value unlock theory; 2) the newly (apparently) amended VZ MVNO agreement; 3) broadband ARPU growth; 4) Connectivity EBITDA growth; 5) 2026 capital spend; 6) wireless net adds, and 7) 2026 FCF.

January 29, 2026 January 29, 2026 1 EN

New Street Research

CMCSA 4Q25 Quick Take: Results mostly in line; Waiting to hear what’s next

Comcast’s results were mostly in line with estimates. Broadband losses and ARPU were in line. On the call, we would be keen to hear about subscriber trends in 1Q. We don’t expect any major changes to the stock price based on these results. What will drive the stock today is commentary on 1Q broadband trends and potential ‘value unlock’ from an NBCU spin.

January 29, 2026 January 29, 2026 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

The DOJ Files an Appeal to Reverse AT&Tâ€™s Acquisition of Time Warner; AT&Tâ€™s Shares Undervalued

What Policies Matter to Telco’s Success: Supply Side or Demand Side? Or Something Else?

CMCSA: The value unlock trade? Nope. No major change in fundamentals

CMCSA 4Q25 Quick Take: Results mostly in line; Waiting to hear what’s next

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe